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Background/aim: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the
standard approach for patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL).
In this study, we report the outcome of the mitoxantrone-melphalan conditioning regimen for lymphoma.
Materials and methods: The study group included 53 patients who were relapsed/refractory HL (n = 14) and NHL (n =
39) and received mitoxantrone and melphalan followed by ASCT. The transplant regimen consisted of mitoxantrone (60
mg/m2) and melphalan (180 mg/m2) followed by peripheral blood stem cell infusion (PBSC).
Results: Prior to high-dose chemotherapy, 37.7% of the patients were in complete remission (CR) and 45.3% were in
partial remission (PR), and 17% had stable or progressive disease. After high-dose chemotherapy and PBSC, 44 out of 51
patients achieved CR (86.2%). CR was achieved in 24 out of 33 patients (72.7%) who were transplanted in a marginally
active phase of the disease. At a median followup of 25.4 months (1.8–131.3 months) after ASCT, 13 patients relapsed/
progressed and 8 patients died. The estimated 2-year overall survival (OS) was 81.9%, and event-free survival (EFS) was
59.3%.
Conclusion: High-dose chemotherapy followed by ASCT is an effective conditioning regimen in relapsed/refractory
lymphoma patients who are undergoing ASCT.
Key words: Lymphoma, relapsed, autologous stem cell transplantation
1. Introduction
Although significant advances have been achieved in the
treatment of non-Hodgkin’s lymphoma (NHL), 40%–
60% of patients still relapse or have treatment-resistant
disease [1]. With conventional salvage regimens, these
patients have a less than 10% chance of achieving a
prolonged disease-free interval. Although the majority
of patients with Hodgkin’s lymphoma (HL) will be cured
with initial therapy, 5%–10% will not achieve complete
remission (CR), and 10%–30% will relapse following
standard therapy. High-dose chemotherapy (HDCT) and
autologous stem cell transplantation (ASCT) is the most
effective treatment and currently the standard approach
for patients with relapsed/refractory NHL and HL. Many
randomized studies have shown significant improvements
in progression-free survival (PFS) and event-free survival

(EFS) with ASCT in relapsed/refractory HL and NHL
[1–3]. Other regimens, such as BCNU (carmustine),
etoposide, cytarabine, melphalan (BEAM), are still
more frequently preferred [4–7]. Carmustine, etoposide,
cyclophosphamide (CBV), carmustine, etoposide,
cytarabine, cyclophosphamide (BEAC), busulfan,
cyclophosphamide (BuCy), busulfan, cyclophosphamide,
etoposide (BuCyE), total body radiation (TBI) containing
regimens (TBI, etoposide, cyclophosphamide), etoposide,
and melphalan (VP-16/Mel) are also used in lymphoma
[2,5,7–14]. Because of carmustine toxicity, other regimens
also used, such as bendamustine containing regimen
[bendamustine, etoposide, cytarabine, melphalan (BeEAM)], fotemustine, etoposide, cytarabine, melphalan
(FEAM), thiotepa containing regimen (TEAM), and using
mitoxantrone instead of carmustine (NEAM) regimen
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[14–17]. Carmustine is not a drug that is easy to prescribe
due to health policies in many countries, [18] including
Turkey. A mitoxantrone-melphalan regimen is preferred
in our center instead of BEAM.
In this retrospective study, we aimed to evaluate the
efficacy of mitoxantrone-melphalan as a conditioning
regimen before ASCT in patients with relapsed/refractory
HL or NHL.
2. Methods
2.1. Patients
Fifty-three consecutive adult patients with relapsed/
refractory NHL or HL who were treated with
mitoxantrone-melphalan and ASCT between June 2001
and December 2017 at Hacettepe University Medical
Faculty Hematology Bone Marrow Transplantation Unit
have been retrospectively evaluated. All of the ethical
considerations had been strictly followed in accordance
with the Helsinki declaration. All of the patients provided
written informed consent for the ASCT procedure. Patients
with primary refractory disease or at least 1 relapse after
standard chemotherapy were eligible for the study. Primary
refractory disease was defined as disease progression
or failing to attain a CR during first-line chemotherapy.
Relapsed disease was defined as disease progression after
disappearance of all clinical and radiographic evidence of
disease for more than 2 months. Relapses occurring within
or after 12 months were considered early and late relapse,
respectively.
Other eligibility criteria included an Eastern
Cooperative Oncology Group (ECOG) performance status
of ≤2 and having adequate organ functions defined by a
serum creatinine level of <2 mg/dL, serum transaminases
less than 2 times the normal value and a bilirubin level
of <2 mg/dL, and cardiac ejection fraction greater than
50% determined by echocardiography. Patients had to
have adequate pulmonary function, defined as a forced
expiratory volume in the first second (FEV 1) and forced
vital capacity (FVC) of >80% of the amount predicted.
Patients were required to have no central nervous system
involvement, and be free of both active infection and
human deficiency virus infection. Patients who were
not given mitoxantrone-melphalan in the transplant
preparation regimen were not included in the study.
2.2. Autologous hematopoietic stem cell transplant regimen
Autologous hematopoietic stem cells were harvested from
patients prior to conditioning by either chemomobilization
with high-dose filgrastim or high-dose filgrastim alone.
Generally we collected 2 × 106 CD34 + cells/kg for the
ASCT. The cumulative anthracycline doses were recorded
to chemotherapy regimens prior to ASCT. Fifty mg/m2
adriamycin for 1 day for cyclophosphamide, adriamycin,
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vincristine, prednisone (CHOP); cyclophosphamide,
adriamycin, etoposide, vincristine, prednisone (CHOEP);
25 mg/m2 adriamycin for 2 days for adriamycin, bleomycin,
vinblastine, dacarbazine (ABVD) regimen, 35 mg/m2
doxorubicin for 1 day bleomycin, etoposide, doxorubicin,
cyclophosphamide, vincristine, procarbazine, prednisone
(BEACOPP) regimen, and 8 mg/m2 mitoxantrone for
fludarabine, cyclophosphamide, mitoxantrone (FCM) were
recorded. The mitoxantrone-melphalan regimen consisted
of mitoxantrone (given over three 1-h administrations at
1-h intervals on day 4, with a total dose of 60 mg/m2/based
on ideal body weight) and melphalan (given over two 1-h
administrations at 1-h intervals on day 1, with a total dose
of 180 mg/m2/based on ideal body weight) followed by
peripheral blood progenitor cell infusion (day 0) [19]. A
granulocyte colony stimulating factor was administered
at 5 mcg/kg/day subcutaneously beginning on day 2 and
continuing until neutrophil recovery.
2.3. Supportive care
All patients received prophylaxis to prevent bacterial,
fungal, viral, and pneumocystis carinii infections.
Antibacterial and antipneumocystis carinii drugs
administered were levofloxacin (500 mg/day, orally) and
trimethoprim-sulfamethoxazole (1 double-strength tablet
twice a day. 2 days per week), respectively. Ciprofloxacine
(500 mg/day) was used as prophylaxis prior to July 2007.
Patients received intravenous (IV) fluconazole (400 mg/
day) from day +1 until engraftment as an antifungal
prophylaxis. The antiviral prophylaxis consisted of IV
acyclovir (500 mg/m2/day, in 2 divided doses) from day
+1 until engraftment. Irradiated packed red blood cells
and single-donor platelet infusions were administered to
maintain hematocrit level above 27% and platelet count
higher than 20 × 109/L, respectively.
2.4. Assessment of response
All patients underwent baseline staging procedures
before ASCT, which included physical examination, chest
X-ray, computed tomography scans or PET-CT, and bone
marrow biopsy. Response to ASCT was determined on
posttransplant day +100, and follow-up visits were done
every 3 months for the first 2 years and then every 4
months for 3 years. Baseline staging investigations were
used as the reference point for subsequent evaluations of
disease response. Disease response was defined according
to standard lymphoma response criteria [20]. Neutrophil
and platelet engraftment were defined as per Center for
International Blood and Marrow Transplant Research
(CIBMTR) [21].
2.5. Statistical analysis
Categorical and continuous variables were expressed
as proportions and medians (minimum–maximum),
respectively. Survival durations were presented as duration
in months ± standard error (SE), 95% confidential interval
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Table. Characteristics of patients.
Total (n = 53)
Age

45 (18–68)

Sex
Male
Female

29 (54.7%)
24 (45.3%)

Diagnosis
HL
NHL
DLBCL
MCL
FL
T-rich B-cell lymphoma
T-cell lymphoma
Gray zone lymphoma
Anaplastic large cell lymphoma
Burkitt lymphoma
EBV-associated B-cell lymphoma
Marginal to DLBCL

14 (26.4%)
39 (73.6%)
18 (33.9%)
6 (11.3%)
4 (7.5%)
2 (3.7%)
3 (5.6%)
2 (3.7%)
1 (1.9%)
1 (1.9%)
1 (1.9%)
1 (1.9%)

Remission duration prior to salvage (n = 46)*
Primary refractory
Early relapse (≤12 months)
Late relapse (>12 months)

5 (9.4%)
22 (41.5%)
19 (35.8%)

Salvage regimen (n = 46)*
R±ICE
R±DHAP
BEACOPP
FCM
R+GDP
R±CHOP
R-DHAP/R-Bendamustin

32 (69.5%)
9 (19.5%)
1 (2.2%)
1 (2.2%)
1 (2.2%)
1 (2.2%)
1 (2.2%)

Assessment pre-ASCT
CR
PR
Stable (refractory) disease
Progressive disease

20 (37.7%)
24 (45.3%)
4 (7.5%)
5 (9.5%)

(CI). The end points of the study were CR rate after
mitoxantrone-melphalan and ASCT, overall survival (OS),
and EFS. OS was defined as the time from ASCT to the
date of death or last follow-up. EFS was defined as at the
time from ASCT to treatment failure (no CR or relapse) or
death from any cause, whichever occurred first. Diseasefree survival (DFS) was calculated in the patients who
attained CR from the time of CR to relapse or remission
in death. Survival curves were calculated according to
the Kaplan–Meier method. A P-value of <0.05 was used
as the criterion for statistical significance. SPSS statistics
17 (SPSS Inc., Chicago, IL, USA) was used for statistical
analyses.

3. Results
3.1. Patient characteristics
Clinical characteristics of patients are summarized in
Table. The median age of the patients was 45 years (18–
68). Of the patients, 73.6% had NHL and 26.4% had HL.
The median duration between diagnosis and ASCT was
22.1 months (2.3–88.9). Previous front-line chemotherapy
consisted of ABVD and R-CHOP for almost all HL and
NHL patients, respectively. Five (9.4%) patients had
primary refractory disease, while 41.5% were in early
relapse, and 35.8% were in late relapse prior to the salvage
regimen (Table). Seven (13.3%) of the patients had
cases of lymphoma in its first CR [2 cases of mantle cell
lymphoma (MCL); 1 case each of transformed marginal
zone lymphoma, Burkitt lymphoma, anaplastic large cell
lymphoma, peripheral T cell lymphoma, and diffuse large
B-cell lymphoma (DLBCL)]. Salvage chemotherapy was a
rituximab (R) when indicated + ifosfamide, carboplatin,
and etoposide (ICE) regimen in 33 (64.2%) of patients;
dexamethasone, cytarabine, and cisplatin (R-DHAP)
in 10 (18.9%) patients; fludarabine, cyclophosphamide,
and mitoxantrone (FCM)’ and 1 patient each was treated
with BEACOPP, gemcitabine, dexamethasone, and
cisplatin (R-GDP), R-CHOP, and sequential R-DHAP/RBendamustine. Thirty-two of 53 [18 DLBCL, 5 MCL, 4
follicular lymphoma (FL), 1 Burkitt lymphoma, 1 EBVassociated B-cell lymphoma, 2 T-cell rich B-cell lymphoma,
1 marginal zone to DLBCL] patients with various B cell
lymphoma histologies received R-containing salvage
regimens. Prior to the mitoxantrone-melphalan regimen,
the median cumulative anthracycline dose was 360 mg/m2
(100 mg/m2–505 mg/m2). Six of 39 NHL patients (15.3%)
had low intermediate risk while 33 of them (84.7%) had
high intermediate risk.
Prior to the transplant regimen, 37.7% and 45.3% of
the patients achieved CR and PR after salvage therapy,
respectively. Eighty-three percent of patients who were
chemosensitive responded to the salvage treatment given
before the transplantation. Seventeen percent of the
patients underwent transplantation with refractory (7.5%)
or progressive (9.5%) disease. The median numbers of
mononuclear cells and CD34+ cells infused were 5.6 ×
108 (1.1–16.8 × 108) and 5.7 × 106/kg (1.3–42.8 × 106),
respectively. Posttransplant median neutrophil and platelet
engraftment durations were 11 (9–17) and 14 (7–41) days,
respectively. All patients engrafted well.
3.2. Response and survival
During a median follow-up of 25.4 months (1.8–131.3) after
ASCT, 8 patients died [1 patient due to early transplantrelated mortality, 4 patients due to relapse/progressive
disease, 3 patients due to other reasons]. At the last followup 45 (84.9%) patients were alive. At posttransplant day
+100, 44 of 51 evaluable patients were in CR. Two patients
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in the early posttransplant period were not evaluated. CR
ratio was 20/20 (100%), 21/24 (87%), and 3/7 evaluable
patients (42%) in patients already in CR, in PR, and
having stable/progressive disease at ASCT, respectively (P
= 0.001).
The 5-year OS, DFS, and EFS projections were 81.9%,
46.5%, and 41.4%, respectively. Median OS duration was
not reached. Median DFS duration was 42.2 months.
Median EFS duration was 38.4 months ± 8.6 (21.5–55.3)
(Figure 1).
According to the pretransplant evaluations, OS was
80.6% in the pretransplant CR group, 91.3% in the PR
group, and 56.3% in the refractory group. However, the
duration of the median OS was not reached in all groups.
There was a marginally statistically significant difference
between the groups, which showed better OS in patients
who are in CR/PR (P = 0.053). DFS was found to be 62.1%
in the pretransplant CR group, 31.8% in the PR group, and
50% in the refractory group. Median DFS duration was not
reached in the CR and refractory groups and was found to
be 35.4 months ± 7.3 (21–49.7) in the PR group. There was
no statistically significant difference between the groups
(P = 0.67). According to the pretransplantation status, EFS
rates were 62.2% in the CR group, 30.5% in the PR group,
and 22.2% in the refractory group. In the CR group, median
EFS was not reached, in the PR group it was 38.4 months
± 7.1 (24.5–52.4), and in the refractory group it was 5.2
months ± 3.9 (0–12.9). There was a statistically significant
difference between the groups (P = 0.01) (Figure 2).
Several factors were evaluated as possible prognostic
indicators of OS and EFS. There was no significant survival
difference between patients with DLBCL, HL, and others.
The 5-year OS and EFS of patients with DLBCL were 75.6%
and 39.2%, respectively, which were not significantly
different from those of patients with HL (90.9% and 66.7%,
respectively) (P = 0.59, P = 0.91).
3.3. Toxicity
Major toxicities of the conditioning regimen were grade
3–4 neutropenia and febrile neutropenia. Grade 3–4
thrombocytopenia and neutropenia were observed in all
patients. All patients had mucositis, 86% had nausea, and
65% had vomiting. Cardiopulmonary insufficiency was
observed in only 1 patient, 29 days after the discharge from
the hospital. Since the cumulative dose of anthracyclines
that was administered during salvage chemotherapies for
the patient was less than 400 mg/m2, the cardiopulmonary
insufficiency observed was attributed to a possible
viral infection. Seven patients had died 100 days after
transplantation. Three of these patients died from sepsis
due to pulmonary infection after an average of 6 months,
3 died from disease activation, and the cause of death
of 1 patient was not found. One patient underwent an
abdominal surgery due to acute intestinal obstruction
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caused by progressive intraabdominal lymphadenopathy
5 months after the transplantation and died due to an
operative complication. The other 2 (3.7%) patients
relapsed on day 120 after the acute onset, and died during
the 6th month after the onset of neutropenic fever and
sepsis with the rescue regimen that started.
4. Discussion
Hodgkin’s and non-Hodgkin’s lymphomas are a group of
diseases that include B- and T-cell lymphomas and occur
in a very wide range of patients. High-dose therapy and
ASCT is the standard treatment for relapsed/refractory HL
and NHL, based on randomized studies, which showed
improved PFS and EFS compared with conventional
therapy [1,22–26]. There are also studies showing that in
chemosensitive NHL, ASCT is superior to chemotherapy
alone in [27,28].
In a study comparing the effects of autologous and
allogenic transplants on DLBCL, the effect of being
chemosensitive and chemoresistant on pretransplantation
in DLBCL patients with autologous transplantation was
examined. The 4-year OS and PFS rates were 60% and 48%,
respectively, and 80% of the patients were chemosensitive.
These rates were lower in the chemoresistant group [29].
Although our study population was more
heterogeneous, our results are comparable with this
EBMT study. The CR rate of our cohort who underwent
transplantation in marginally active disease (PR/
refractory) was found to be 72.7% after ASCT. A median
follow-up of 25.4 months was obtained. The 5-year OS and
PFS rates were 81.9% and 46.5%, respectively, and 83% of
the patients were chemosensitive (CR 37.7%, PR 45.3%).
In another recent study, the 3-year OS and PFS rates
were 86% and 78% respectively, in CR at ASCT HL
patients and the other (no-CR) the rates were found to
be lower [30]. On the other hand, in our study, the 5-year
OS and EFS rates were 90.9% and 66.7%, respectively, in
HL patients. However, in our study HL patients were not
evaluated before transplantation due to the low number
of patients. Similarly, our OS rates in HL were similar to
this study although instead we present the overall OS rate,
including the chemosensitive and chemoresistant groups
together.
A variety of high-dose conditioning regimens have
been available for ASCT in HL and NHL, but no specific
regimen has been demonstrated to be superior. Prospective
trials have not directly compared to different preparative
regimens and settings for ASCT. The choice of conditioning
regimen is influenced by patient comorbidities, short- and
long-term toxicities, and institutional preferences. In our
center’s previous study, a sequential 3-phase regimen
in 40 HL and NHL patients has been performed, with
conditioning regimen mitoxantrone-melphalan [19]. In
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Figure 1. The 5-year OS, DFS, and EFS projections of the patients.

that study, the CR rate (35 in 39 evaluable patients) was
90%. The median follow-up was 32 months. The 4-year
OS and EFS rates of the patients were 72.2% and 55.3%,
respectively [19]. In this study, the OS rate is comparable
to the previous study [19]. In another study, the effect of
transplant preparation regimen on progression and relapse

of NHL and HL autologous stem cell transplant recipients
was examined and regimens of HL and NHL were shown
to have different effects [5]. The 3-year PFS and OS rates
were 51% and 64% in the group using BEAM for NHL.
They indicated that BEAM is superior for DLBCL, but
not in FL and MCL [5]. On the other hand, in our study,
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Figure 2. The OS, DFS, EFS durations of the patients according to the pretransplant evaluations.

DLBCL group’s 5-year OS rate was 75.6%, and this result is
better than BEAM. In patients with HL, the use of Bu/Cy
or TBI-based regimens has been shown to increase relapse
risk compared to the groups using BEAM or CBV [5]. They
have reported the 3-year PFS and OS rates as 62% and
79%, respectively, in HL patients who received the BEAM
regimen [5]. In our study, the 5-year EFS and OS rates of
HL patients who were given the mitoxantrone-melphalan
regimen were superior to the BEAM groups reported in
the literature. In [5], the 1-year transplant related mortality
(TRM) was found as 4% in patients receiving BEAM,
and the TRM was not different in NHL/HL groups with
different conditioning regimens. On the other hand, in our
study there was only 1 case where possible cardiotoxicity
was observed that could be considered a major toxicity.
Therefore, in our study the first 100-day mortality rate was
found as 1.8%.
In a recent article, another transplant regimen of
lomustine, etoposide, cytarabine, and cyclophosphamide
(LACE) was used because BCNU could not be provided.
The patient population was heterogeneous [30]. The 3-year
OS and PFS were found nearly similar to our present study
(70% and 58%). The TRM was found as 7%.
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In another study, bendamustine was used instead
of carmustine because it is hard to access carmustine in
France. Bendamustine-related severe renal toxicities were
observed [31]. In contrast to this, our study demonstrated
that mitoxantrone-melphalan could be considered as a
somewhat cost-effective regimen for relapsed refractory
lymphoma for many reasons. Firstly, no serious toxicity
was observed in any of the patients (except only one)
with mitoxantrone-melphalan. This data favors the safety
of mitoxantrone-melphalan with its low toxicity profile.
Secondly, mitoxantrone-melphalan showed favorable
OS, EFS, and DFS rates, which confirms the extension
of survival durations with the mitoxantrone-melphalan
regimen. Thirdly, the regimen should not be a financial
disaster for the patients. Mitoxantrone-melphalan is a
relatively cheap option. Mitoxantrone is one of the oldest
regimens, and it is preferred in our center because it is a
cost-effective conditioning regimen option in our country.
To summarize, in our study, 5-year estimated OS
and 5-year estimated EFS rates were 81.9% and 41.4%,
respectively. The effective use of clinical trials after the
relapses after the transplantations could be the reason
for the difference between the OS and EFS rates. The OS,
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EFS, DFS rates according to the response (pretransplant
evaluation) given to the salvage chemotherapy regimen
before transplantation were compared. The EFS rate was
higher in the group with CR before transplantation. The
highest OS rate was in the PR group.There was no difference
among the groups in rates of DFS. This interesting data
could be explained by the tendency of initiation of new
generation agents and checkpoint inhibitors (brentuximab
vedotin, nivolumab) to PR patients, or faster admission to
clinical trials of PR patients compared to CR patients.
The major limitation of this study is its retrospective
design. Another limitation is the low number of patients

in both groups. The comparisons regarding the BEAM
conditioning regimen could not be performed because of
the insufficient number of patients.
In conclusion, high-dose chemotherapy followed by
ASCT is an effective conditioning regimen in relapsed/
refractory lymphoma patients who are undergoing ASCT.
In this retrospective analysis, the use of the mitoxantronemelphalan was found to be an effective conditioning
regimen for ASCT in relapsed/refractory lymphoma.
Future large controlled prospective studies are needed
in order to further elucidate the roles of different ASCT
conditioning regimen for lymphoma.
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